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Abstract
OBJECTIVE: To compare the efficacy of integrated
Chinese and Western Medicine with that of only
Western Medicine for the treatment of malignant
ascites.
METHODS: All randomized controlled trials (Janu-
ary 2004 to March 2013) from the China National
Knowledge Infrastructure Database, Chinese Bio-
medical Literature Database, and Wanfang Data-
base were searched with keywords. Meta-analysis
was conducted by combining the odds ratios of
the individual studies. Review Manager 5.0 was
used for the analysis.
RESULTS: One thousand one hundred and fifty-six
patients from 19 randomized controlled trails were
included. Of them, 630 patients were treated with
integrated Chinese and Western Medicine (the inte-
grative group), and 526 patients were treated with
Western Medicine alone (the control group). The
Meta-analysis showed that the total effective rate
was 78.73% in the integrated group, and 59.13% in
the control group. The effective percentage was sig-
nificantly higher in the integrative group than that
of the control group [OR = 2.85, 95% CI (2.16，3.74),
P < 0.01].
CONCLUSION: The short-term curative effect in the
integrative group was better than that in the con-
trol group. Integrative medicine may be beneficial
for malignant ascites.
© 2015 JTCM. All rights reserved.
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INTRODUCTION
Malignant ascites is a common complication of late ma-
lignant tumors. Ascites is a symbol of advanced cancer,
and seriously affects patient quality of life. Patients in
poor physical condition have numerous clinical symp-
toms, and often cannot tolerate chemotherapy or radio-
therapy. Moreover, patients in the late stages of cancer
are usually not sensitive to chemotherapy, radiotherapy,
or other anti-tumor strategies, and survival time is usu-
ally only 3-6 months. Therefore, malignant ascites is a
major problem in clinical oncology.
Many studies have investigated the treatment of malig-
nant ascites with Traditional Chinese Medicine
(TCM). Therefore, therapeutic principles and effective
prescriptions of Chinese medicine have been estab-
lished. TCM plays an increasingly important role in
treating malignant ascites. In the present study, we
searched randomized controlled trails (RCTs) (pub-
lished from January 2004 to March 2013 in China) for
studies investigating TCM treatment of malignant asci-
tes. In this Meta-analysis, we assessed the disease enti-
ties, syndrome differentiation, therapeutic principles
and methods, and curative effects.
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MATERIALS ANDMETHODS
Literature selection strategy
We searched articles from the China National Knowl-
edge Infrastructure Database, Chinese Biomedical Lit-
erature Database, and Wanfang Database from January
2004 to March 2013. Medical keywords user were:
"cancerous ascites," "cancerous abdominal effusion,"
"malignant ascites," "malignant abdominal effusion,"
"Traditional Chinese Medicine," "Chinese herbal medi-
cine," and "Integrated Chinese and Western Medicine.
" We reviewed all retrieved articles to find relevant sta-
tistics and analysis.
Inclusion criteria
Studies were included if: (a) they could be defined as
controlled trials; (b) the patients in the study were diag-
nosed to have malignant ascites by cytology or patholo-
gy; (c) the general data between the groups in age, gen-
der, stages, and pathological types were comparable.
Exclusion criteria
We excluded any non-controlled trials, theoretical dis-
cussions, literature reviews, and studies in which the da-
ta could not be used or was not in accordance with the
inclusion criteria.
Therapeutic methods for malignant ascites
In the control group, only Western Medicine treatment
was adopted, including abdominocentesis, ascites draw-
ing, and cisplatin and/or interleukin 2 (IL-2) peritone-
al perfusion. In the integrative group, conventional
Western Medicine treatment was used plus TCM treat-
ment. TCM treatments included decoctions for oral
administration, external application, and peritoneal
perfusion.
Criteria for short-term curative effect
Ascites was assessed by ultrasound in reference to Re-
sponse Evaluation Criteria in Solid Tumors. Complete
response: disappearance of ascites, confirmed at ≥ 4
weeks; partial response: ≥ 50% decrease from baseline,
conﬁrmed at ≥ 4 weeks; progressive disease: ≥ 25% in-
crease from baseline; stable disease: met neither PR nor
PD criteria, conﬁrmed at ≥ 4 weeks. The total response
rate was CR + PR.
Data extraction and statistical analysis
The following information was extracted from each of
the eligible included publications: disease entities,
TCM syndrome types, TCM therapeutic principles
and methods, and curative effect. We performed a sys-
tematic review following recommendations of the Co-
chrane Collaboration (Higgins 2011)1 using Review
Manager 5 (RevMan 2011),2 produced and updated by
Cochrane Collaboration. The between-study heteroge-
neity was assessed using the Cochran's Chi-square test,
if P > 0.05, a fixed-effect model was used; if P < 0.05, a
random-effect model was used. The Meta-analysis was
conducted by combining the odds ratios of the individ-
ual studies and followed the sensitivity analysis. Funnel
plots were used to assess the potential publication bias.
Data synthesis
Data synthesis involved number of the patients, TCM
syndrome types, Chinese herbal medicines used, and
therapeutic effects.
RESULTS
Results of literature retrieval
Sixty-four references were collected initially, and 19 pa-
pers met all the inclusion criteria.3-21 All non-controlled
trials were excluded, and TCM theoretical research, re-
views, animal experiments, case reports, and nursing re-
search were also excluded. A total of 1156 patients
were reported in 19 studies, including 526 patients
treated with Western Medicine (the control group) and
630 patients treated with integrated Chinese and West-
ern Medicine (the integrative group). The control
group was treated with abdominocentesis and ascites
drawing, followed by IL-2 and/or cisplatin intraperito-
neal injection. The integrative group was treated with
Western Medicine and at the same time given Chinese
herbal medicines for oral administration or external ap-
plication.
Disease entity
Disease entities of the patients included liver cancer
(426 cases), ovarian cancer (238 cases), colorectal can-
cer (154 cases), gastric cancer (145 cases), pancreatic
cancer (32 cases), lung cancer (22 cases), breast cancer
(11 cases), cervical cancer (5 cases), small intestinal can-
cer (3 cases), esophageal carcinoma (3 cases), bile duct
carcinoma (2 cases), and other types of cancer (33 cas-
es). Disease entities were not presented in one study
that included 45 patients. Thirty-seven gastrointestinal
cancer cases were reported in another study.
TCM syndrome types
No unified standards were used for differentiation of
the TCM syndrome types. There were no TCM syn-
drome types listed in nine papers, especially for study
of externally used Chinese herbs. The TCM syndrome
types are generally: Qi stagnancy and toxin stasis syn-
drome (192 cases), Qi deficiency and blood stasis syn-
drome (185 cases), Qi deficiency and water retention
syndrome (170 cases), spleen-kidney Yang deficiency
syndrome (120 cases), deficiency of Yin and water-heat
accumulation syndrome (80 cases), and damp obstruc-
tion because of spleen deficiency (61 cases).
Publication bias
The symmetry of the reversed funnel plot indicates no
publication bias (Figure 1).
The funnel plot is produced with OR as the X-axis,
which represents the short-term effective rate of the in-
tegrative group versus the control group, and with log
[OR] as the Y-axis. The included studies present a sym-
metrical funnel plot, indicating no publication bias.
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TCM syndrome differentiation, treatment variation,
and medications
The TCM therapeutic principles adopted were: tonify-
ing Qi, strengthening the spleen, promoting diuresis,
warming Yang, and activating blood. Six studies evalu-
ated self-made oral prescriptions. Four studies evaluat-
ed modified oral prescriptions, including Zhenwu de-
coction (two studies), Zhuling decoction (one study),
and Jiaweiwuling San (one study). Three studies evalu-
ated Chinese patent medicines for peritoneal perfu-
sion, including elemene injection, Kanglaite injection,
and javanica oil emulsion injection combined with
Kanglaite injection. Three studies evaluated self-made
prescriptions for external application on the Shenque
acupoint. Self-made herbal electuary ointment was
used on the abdominal wall in two studies. One study
evaluated Fufangkushen injection for intravenous infu-
sion. The most commonly-used medicinal herbs were:
Huangqi (Radix Astragali Mongolici), Baizhu (Rhizoma
Atractylodis Macrocephalae), Guizhi (Ramulus Cinnamo-
mi), Fuling (Poria), Zhuling (Polyporus), Zexie (Rhi-
zoma Alismatis), Dafupi (Pericarpium Arecae), Danggui
(Radix Angelicae Sinensis), and Ezhu (Rhizoma Curcum-
ae Phaeocaulis).
Short-term curative effect
Curative effects in the integrative group and control
group were presented in 19 studies (Figure 2). In the
integrative group, 630 patients received TCM treat-
ment combined with Western Medicine treatment. In
the control group, 630 patients received only Western
Medicine treatment. Heterogeneity was not found in
these studies (heterogeneity P = 0.67), so the fixed-ef-
fect model was used. The results showed that the total
effective rate was 78.73% in the integrative group, and
59.13% in the control group. The total effective rate of
the integrative group was significantly higher than that
of the control group [OR = 2.85, 95% CI (2.16-3.74),
P < 0.01]. Therefore, the short-term curative effect of
the integrative treatment was better than that of West-
ern Medicine treatment.
DISCUSSION
Malignant ascites is a clinical manifestation of
late-stage malignant tumors. Radiotherapy and chemo-
therapy cannot ameliorate malignant ascites. At pres-
ent, Western Medicine treatments for malignant ascites
mainly include dieresis, abdominal paracentesis, perito-
neal drainage, chemotherapy or intraperitoneal chemo-
therapy, and intraperitoneal immunotherapy. These
treatments have their advantages and shortcomings,
so the total effects are limited.22 TCM treatments for
malignant ascites include oral Chinese medicines,
and Chinese medicinal preparations for external use
or peritoneal perfusion. These treatments may reduce
malignant ascites and ameliorate clinical symptoms.
In addition, TCM treatments are convenient and
cheap, and usually have fewer side effects. These
medicines can therefore be used by all the patients in
varying conditions.23,24
We analyzed 19 clinical studies from China. The dis-
ease entities of patients in descending frequency were:
liver cancer; ovarian cancer, gastric cancer, and colorec-
tal cancer; lung cancer, breast cancer, and pancreatic
cancer; and cervical cancer, small intestinal cancer, and
esophageal carcinoma. These are in accordance with re-
lated clinical reports.
TCM diagnosis and treatment are based on an overall
analysis of the illness and the patient's condition. This
is the unique characteristic and advantage of TCM.
Figure 1 Funnel plot of the included studies
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Figure 2 Comparison of the short-term curative effect for treating malignant ascites
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However, the TCM syndrome types, therapeutic princi-
ples, and methods are somewhat different in the 19
studies. Moreover, the preparations used are made by
the researchers themselves with no unified standards.
Therefore, the clinical outcomes are difficult to be pop-
ularize and standardize. Nevertheless, the most com-
mon TCM therapeutic principles are strengthening the
spleen, tonifying Qi, and activating Qi to excrete water.
Huangqi (Astragali Radix), Fuling (Poria Cocos), Zhul-
ing (Polyporus Umbellatus), and Dafupi (Pericarpium
Arecae) are the most commonly-used effective drugs for
treating malignant ascites.
Integrated Chinese and Western Medicine treatment
was adopted in the integrative group. In this group, the
therapeutic effects were much better than those in the
control group. Therefore, TCM could be effective for
treating malignant ascites. However, low quality stud-
ies are problematic in the consulted literatures. All 19
studies were single-centered with a non-blind method,
and had relatively small sample sizes. The randomization
methods were not illustrated, and no unified authorita-
tive standards were used. A more convincing conclusion
needs scientific and precise study design. Therefore,
high-quality, multi-centered, and randomized con-
trolled trials with large sample sizes are necessary.
REFERENCES
1 Higgins JPT, Green S: Cochrane handbook for systematic
reviews of interventions. Cochrane Collaboration, Version
5.1.0 (updated March 2011). Available from URL: http://
handbook.cochrane.org.
2 The Nordic Cochrane Centre, The Cochrane Collabora-
tion. Review Manager (RevMan). 5.1. Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration,
(updated 2011). Available from URL: http://ims.cochrane.
org/revman.
3 Wu D, Bao WG, Ding YH, et al. Clinical and experimen-
tal study on xiaoshui decoction for primary liver cancer
caused ascites. Chin J Integr Med 2005; 25(12): 1066-
1069.
4 Xiao MW, Duan P. Clinical observation on intraperitone-
al medicine plus oral TCM for cancerous ascites. Sichuan
Zhong Yi 2004; 22(9): 47-48.
5 Bao WQ. Clinical study on Zhenwu decoction combined
with cisplatin for treatment of ascites caused by primary
liver cancer. Shi Yong Zhong Xi Yi Jie He Lin Chuang
2009; 9(2): 21-22.
6 Zhang DJ, Wei MM, Wang SH, et al. Clinical study on
Baoganlishui decoction plus intraperitoneal chemotherapy
for treatment of ascites due to primary liver cancer. Zhong
Guo Zhong Yi Yao Xin Xi Za Zhi 2010; 17(3): 77-78.
7 Zhang H, Zhang XY, Pan XP. Clinical observation on Jia-
weizhulin decoction for cancerous ascites. Zhong Guo
Zhong Yi Yao Xin Xi Za Zhi 2009; 16(11): 71-75.
8 Zhang H, Wang J. Clinical observation on the prescrip-
tion for nourishing Qi and promoting diuresis in combina-
tion with abdominal paracentesis in treatment of malig-
nant ascites. Zhong Guo Zhong Yi Ji Zheng 2012; 21
(12): 2009-2010.
9 Luo HY, Xu K, Liu CY. The effect of carcinomatous hy-
droperitonia by instillating β-elememe milk into abdomi-
nal cavity after hydroperitonia ultrafiltration refusion.
Zhong Guo Zhong Yi Yao Xin Xi Za Zhi 2004; 11(5):
388-390.
10 Yan M, Bai XJ. Twenty-eight cases of malignant ascites
treated by Yiyiren injection plus intraperitoneal chemo-
therapy. Yunnan Zhong Yi Zhong Yao Za Zhi 2008; 29
(10): 20-21.
11 Gong HW, Tan XY, Luo XL. Injection of compound Kuh-
seng and cisplatin into abdominal cavity in treatment of
45 cases of malignant ascites. Zhong Wai Yi Liao 2008; 27
(26): 65-66.
12 Zhang X, Zhou JW, Hu WJ. Clinical observation on Xiao-
gusan externally used for cancerous ascites. Neimenggu
Zhong Yi Yao 2009; 28(24): 2-3.
13 Dong ME, Li J. Neijinzhumao decoction in treatment of
56 cases of cancerous ascites. Shanxi Zhong Yi 2007; 28
(4): 396-397.
14 Zhu BY, Tang GM, Peng SZ. Kanglaite injection and
intraperitoneal catheter drainage for malignant ascites.
Shi Yong Zhong Liu Xue Za Zhi; 2010; 24(2): 152-154.
15 Zhou LR, Zhang NS. Seventy cases of malignant ascites
treated by Jiaweiwuling San. Shi Yong Zhong Yi Nei Ke
Za Zhi 2010; 24(6): 70-71.
16 Luo CG, Yang XG, Lu YX. Therapeutic effects of Qi-
luogao plus intraperitoneal chemotherapy for malignant as-
cites. Guangxi Zhong Yi Xue Yuan Xue Bao 2010; 13(3):
10-12.
17 Wei GQ, Zhe Z, Zhang T, et al. Clinical research on ma-
lignant ascites treated by external application of herbal
compound formulae. Shi Jie Zhong Xi Yi Jie He Za Zhi
2011; 6(8): 677-679.
18 Yang Z, Xu YM, Tang WJ, et al. Zhenwu Decoction plus
intraperitoneal chemotherapy for treatment of ascites
caused by ovarian cancer. Shi Yan Fang Ji Xue Za Zhi
2010; 16(16): 195-196.
19 Fan HJ, Yao RS, Xu CY, et al. Therapeutic effects of navel
moxibustion and intraperitoneal catheter drainage with
drug for malignant ascites. Zhong Guo Zhong Yi Yao
Xian Dai Yuan Cheng Jiao Yu 2012; 10(5): 34-35.
20 He YM, Xue SF. 31 cases of malignant ascitse treated by
Xiaoshui formula Ⅱ. Zhong Yi Za Zhi 2006; 47(5):
355-357.
21 Jin QM, Zhao Y, Ou YY, et al. 30 cases of malignant
ascites due to ovarian cancer treated by external applica-
tion of herbal compound formulae plus intraperitoneal
chemotherapy. Zhong Yi Yao Dao Bao 2011; 17(9):
428-430.
22 Long XA, Yang DM, Niu LZ, et al. The progress in treat-
ment of malignant ascites. Guo Ji Xiao Hua Bing Za Zhi
2013; 33(3): 155-159.
23 Zheng WM. The progress in treatment of primary liver
cancer caused ascites by Integrated medicine. Neimenggu
Zhong Yi Yao 2012; 31(13): 64-65.
24 Xu Y, Li P, Chen J, et al. The Mechanism of malig-
nant ascites and review of the Traditional Chinese
Medicine therapy. Zhong Yi Za Zhi 2011; 52(14):
1249-1252.
14
